ATAI Life Sciences N.V. (NASDAQ: ATAI)
$1.4500
+0.1200 ( +3.57% ) 806.6K
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Market Data
Open
$1.4500
Previous close
$1.3300
Volume
806.6K
Market cap
$244.99M
Day range
$1.3250 - $1.5000
52 week range
$1.0300 - $2.8500
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 4 | Insider transactions | 1 | Jan 10, 2025 |
| 8-k | 8K-related | 19 | Jan 10, 2025 |
| 3 | Insider transactions | 2 | Jan 10, 2025 |
| 3 | Insider transactions | 2 | Jan 10, 2025 |
| 4 | Insider transactions | 1 | Jan 03, 2025 |
| 3 | Insider transactions | 2 | Dec 13, 2024 |
| 10-q/a | Quarterly Reports | 102 | Nov 14, 2024 |
| 8-k | 8K-related | 58 | Nov 13, 2024 |
| 10-q | Quarterly Reports | 102 | Nov 13, 2024 |
| 4 | Insider transactions | 1 | Oct 04, 2024 |